We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for INSYS Therapeutics' (INSY) Q3 Earnings?
Read MoreHide Full Article
INSYS Therapeutics, Inc. is scheduled to report third-quarter 2018 results on Nov 5, after market close.
Last reported quarter, the company’s loss per share missed the Zacks Consensus Estimate by 120%. Moreover, the company missed estimates in three of the trailing four quarters, the average miss being 62.2%.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Similar to the previous quarter, INSYS Therapeutics is expected to see improvement in the prescriptions for its core product — SUBSYS. Led by inclusion in the formularies of several managed care accounts, optimized territory alignment, improvisation and upgradation of commercial sales team and Health Educator programs, the company for the first time in seven quarters, sequentially gained prescription share in the transmucosal immediate-release fentanyl (TIRF) market. Notably, the company’s prescription share rose around 300 basis points to 30.1% from January to June.
Riding on the initial success of its patient access and educational programs, the company is expected to continue witnessing improvements in prescriptions of SYNDROS. INSYS Therapeutics saw a sequential net revenue growth of 56% in the previous quarter, marking the first quarter where SYNDROS net revenues reached $1 million.
However, expired product returns have been negatively impacting the company’s top line. The company has undertaken certain corrective measures like increasing the minimum shelf life of inventory and better match the production schedule with the current demand trend. Based on these actions, management expects the sales returns scenario to have improved starting the third quarter of 2018.
Overall, the Zacks Consensus Estimate for third-quarter total revenues is pegged at $22.6 million, indicating a decline of 26.3% from the prior-year quarter.
Here’s What Our Quantitative Model Predicts:
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
INSYS Therapeutics has a Zacks Rank #3 and an Earnings ESP of 0.00%, a combination that does not hint at an earnings beat.
The Zacks Consensus Estimate of a loss of 20 cents per share reflects an improvement of 4.8% on a year-over-year basis.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat in their upcoming quarterly results.
Quidel Corporation (QDEL - Free Report) has an Earnings ESP of +10.55% and a Zacks Rank #3.
Myriad Genetics, Inc. (MYGN - Free Report) has an Earnings ESP of +9.1% and a Zacks Rank #3.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
What's in Store for INSYS Therapeutics' (INSY) Q3 Earnings?
INSYS Therapeutics, Inc. is scheduled to report third-quarter 2018 results on Nov 5, after market close.
Last reported quarter, the company’s loss per share missed the Zacks Consensus Estimate by 120%. Moreover, the company missed estimates in three of the trailing four quarters, the average miss being 62.2%.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Similar to the previous quarter, INSYS Therapeutics is expected to see improvement in the prescriptions for its core product — SUBSYS. Led by inclusion in the formularies of several managed care accounts, optimized territory alignment, improvisation and upgradation of commercial sales team and Health Educator programs, the company for the first time in seven quarters, sequentially gained prescription share in the transmucosal immediate-release fentanyl (TIRF) market. Notably, the company’s prescription share rose around 300 basis points to 30.1% from January to June.
Riding on the initial success of its patient access and educational programs, the company is expected to continue witnessing improvements in prescriptions of SYNDROS. INSYS Therapeutics saw a sequential net revenue growth of 56% in the previous quarter, marking the first quarter where SYNDROS net revenues reached $1 million.
Insys Therapeutics, Inc. Price and EPS Surprise
Insys Therapeutics, Inc. Price and EPS Surprise | Insys Therapeutics, Inc. Quote
However, expired product returns have been negatively impacting the company’s top line. The company has undertaken certain corrective measures like increasing the minimum shelf life of inventory and better match the production schedule with the current demand trend. Based on these actions, management expects the sales returns scenario to have improved starting the third quarter of 2018.
Overall, the Zacks Consensus Estimate for third-quarter total revenues is pegged at $22.6 million, indicating a decline of 26.3% from the prior-year quarter.
Here’s What Our Quantitative Model Predicts:
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
INSYS Therapeutics has a Zacks Rank #3 and an Earnings ESP of 0.00%, a combination that does not hint at an earnings beat.
The Zacks Consensus Estimate of a loss of 20 cents per share reflects an improvement of 4.8% on a year-over-year basis.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat in their upcoming quarterly results.
PerkinElmer has an Earnings ESP of +1.45% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Quidel Corporation (QDEL - Free Report) has an Earnings ESP of +10.55% and a Zacks Rank #3.
Myriad Genetics, Inc. (MYGN - Free Report) has an Earnings ESP of +9.1% and a Zacks Rank #3.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>